Evidence map›Paper›PMID 37091148›Full record

ArticleFrontiers in oncology2023

Somatic alterations of

Tanya Jindal, Xiaolin Zhu, Rohit Bose, Vipul Kumar, Edward Maldonado, Prianka Deshmukh, Chase Shipp, Stephanie Feng, Michelle S Johnson, Austin Angelidakis and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Tanya JindalHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Xiaolin ZhuHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Rohit BoseHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Vipul KumarHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Edward MaldonadoHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Prianka DeshmukhHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Chase ShippHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Stephanie FengHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Michelle S JohnsonHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Austin AngelidakisHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Daniel KwonHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Hala T BornoHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Ivan de KouchkovskyHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Arpita DesaiHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Rahul AggarwalHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Lawrence FongHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Eric J SmallHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Anthony WongHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Sima PortenHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Jonathan ChouHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Terence FriedlanderHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
Vadim S KoshkinHelen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA, United States.
University of California, San Francisco · USUCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

Determinants of response to cancer immunotherapyR35CA253175 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Lawrence Fong · 2021 to 2026
$5.8M
Defining the roles of PPARgamma and TGFbeta in regulating NECTIN4 and resistance to NECTIN4-targeting therapiesK08CA273514 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jonathan Chou · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA273514NCI NIH HHS R35 CA253175
6 · The paper itself

Abstract

Background: Enfortumab vedotin (EV) is an antibody-drug conjugate approved for patients with treatment-refractory advanced urothelial carcinoma (aUC), however data on biomarkers of response is lacking. Methods: We retrospectively identified all aUC patients at our institution who received EV monotherapy and had next-generation sequencing (NGS) data available. Patients were considered responders if they had a complete response or partial response on restaging scans during treatment. Observed response rate (ORR) was evaluated by local investigator and compared between responders and non-responders using Chi-squared test. A univariable analysis was conducted using the Cox proportional hazard test to assess for associations between baseline characteristics and most common somatic alterations (in ≥10% of patients) with patient survival outcomes [progression-free survival (PFS) and overall survival (OS)]. Somatic alterations were then individually evaluated in separate multivariate models while accounting for patient and clinical characteristics using Cox regression models. Results: Among 29 patients treated with EV monotherapy, 27 had available NGS data. Median age was 70, 24 (83%) were men, 19 (62%) were Caucasian, 15 (52%) had pure urothelial histology and 22 (76%) had primary tumor in the bladder. ORR was 41%, and PFS and OS for the overall cohort were 5.1 months and 10.2 months. Responders were enriched among patients with Conclusion: In this single-center retrospective analysis of aUC patients treated with EV, presence of

Indexed as

antibody drug conjugate (ADC)enfortumab vedotingenetic markersnext generating sequencingurothelial carcinoma

Identifiers

PMID37091148
PMCPMC10113661
OpenAlexW4362622597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.